Endogenous innovations in the pharmaceutical industry

Journal of Evolutionary Economics

Volumn 17, Issue 4, 2007, Pages 473-515

  Cerda, Rodrigo A ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Endogenous innovations; Market size; Pharmaceutical industry; Population

Indexed keywords

EID: 34547306408     PISSN: 09369937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00191-007-0059-3     Document Type: Article

References (32)

1. Almon S (1965) The distributed lag between capital appreciations and expenditures. Econometrica 33:178-196
2. Anderson R, DeTurk P (2002) United States life tables. In: 1999 national vital statistics report, vol 50, no 6
3. Baily M (1972) Research and development costs and returns: the U.S. pharmaceutical industry. J Polit Econ 80(1):70-85
4. Cutler D, McClellan M, Newhouse JP, Remler D (1998) Are medical prices declining? Evidence for Heart Treatments. Q J Econ 113(4):991-1024
5. DiMasi JA, Hansen RW, Grabowski HG, Lasagna L (1991) Cost of innovation in the pharmaceutical industry. J Health Econ 10:107-142
6. DiMasi JA, Seibring M, Lasagna L (1994) New drug din the United States from 1963 to 1992. Clin Pharmacol Ther 55(6):609-22
7. Geoffard P, Philipson T (2002) Pricing and RND when consumption affects longevity. RAND J Econ 33(1):85-95
8. Grabowski H (1968) The determinants of industrial research and development: a study of the chemical, drug and petroleum industries. J Polit Econ 76(2):292-306
9. Grabowski G, Thomas LG, Vernon J (1978) Estimating the effects of regulation on innovation: an international comparative analysis of the pharmaceutical industry. J Law Econ 21(1):133-163
10. Grabowski HG, Vernon JM (1981) The determinants of R&D expenditures. In: Helms RB (ed) Drugs and health. AEI Press, Washington
11. Grabowski H, Vernon J (1992) Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 drug act. J Law Econ 35(2):331-350
12. Grabowski H, Vernon J (1994) Returns to RND on new drug introductions in the 1980s. J Health Econ 13:383-406
13. Grabowski H, Vernon J (2000) The determinants of pharmaceutical research and development expenditures. J Evol Econ 110:201-15
14. Grabowski H, Vernon J, DiMasi J (2002) Returns on RND for 1990s new drug introductions. PharmacoEconomics 20(Suppl 3):11-29
15. Grossman M (1972) On the concept of health capital and the demand for health. J Polit Econ 80:223-250
16. Hansen RW (1979) The pharmaceutical development process: estimates of current development costs and times and the effects of regulatory changes. In: Chien RI (ed) Issues in pharmaceutical economics. Lexington Books, Lexington, MA, pp 151-187
17. Lichtenberg F (1998a) The allocation of publicaly-funded biomedical reaserch. NBER working papers series, working paper 6601
18. Lichtenberg F (1998b) Pharmaceutical innovations as a process of creative destruction. Mimeo, Columbia University
19. Lichtenberg F (2001) The effect of new drugs on mortality rates fron rare diseases and HIV. NBER working papers series, working paper 8677
20. Lichtenberg F (2002) Sources of U.S. Longevity Increase, 1960-1997. NBER working papers series, working paper 8755
21. Lichtenberg F (2003) The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001. NBER working papers series, working paper 9754
22. Lichtenberg F (2006) The impact of new laboratory procedures and other medical innovations on the health of Americans, 1990-2003: evidence from longitudinal, disease level-data. NBER working papers series, working paper 12120
23. Mansfield E (1963) Intrafirm rates of diffusion of an innovation. Rev Econ Stat 45(4):348-359
24. Mansfield E (1969) Industrial research and development: characteristics, costs and diffusion of results. Amer Econ Rev (Papers and proceedings) 59(2):65-71
25. Mansfield E (1985) How rapidly does new industrial technology leak out? J Ind Econ 34(2): 217-223
26. Mundlack Y (1981) On the concept of non-significant functions and its implications for regression analysis. J Econom 16(1):139-149
27. Newhouse JP (1992) Medical care cost: how much welfare loss? J Econ Perspect 6(3):3-21
28. Peltzman S (1973) An evaluation of consumer protection legislation: the 1962 drug amendment. J Polit Econ 81:1049-1091
29. Scherer FM (2001) The link between gross profitability and pharmaceutical RND spending. Health Aff 20(5):136-140
30. Steffensen F, Sorensen F, Olesen F (1999) Diffusion of new drugs in Danish general practice. Fam Pract 16:407-413
31. U.S. Bureau of the Census (2001) Statistical abstract of the United States, various editions. U.S. Bureau of the Census, Washington, DC
32. Vernon J, Gusen P (1974) Technological change and firm size: the pharmaceutical industry. Rev Econ Stat 56(3):294-302